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CO2 capture and storage (CCS) has been proposed for two Norwegian gas-fired power plants as 
a measure to reduce CO2 emissions to the atmosphere. A leading technology for CO2 capture is 
through the use of amines. The CO2 and Amines Screening Study Project began with Phase I in May 
2008. The project was initiated by the Norwegian Institute for Air Research (NILU). This report is the 
contribution from the Norwegian Institute of Public Health to Phase I of the project. 
The project was graciously sponsored by the following: 
•	 Gassnova SF (CLIMIT) 
•	 Statoil Hydro ASA 
•	 Shell Technology Norway AS 
The following institutes participated in the project: 
•	 Centre for Theoretical and Computational Chemistry (CTCC) Department of Chemistry  
at the University of Oslo, responsible for the theoretical study on the atmospheric  
degradation of selected amines 
•	 Norwegian Institute of Public Health (FHI), responsible for the effects to human health 
•	 Norwegian Institute for Nature Research (NINA), responsible for the effects to  
terrestrial ecosystems 
•	 Norwegian Institute for Water Research (NIVA), responsible for the effects on  
freshwater ecosystems 
•	 Norwegian Institute for Air Research (NILU), responsible for project management/ 
coordination, including the chemical screening report, models report, worst case study  
report, and the summary report 
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Health effects of different amines  
relevant for CO2 capture
Monoethanolamine (MEA), piperazine, aminomethyl-
propanol (AMP) and methyldiethanolamine (MDEA) 
appear to be relevant compounds for the capture of 
CO2 in gas-fired power stations MEA and piperazine 
have during several years been used in various indus-
tries and consumer products and may represent a 
significant potential for human exposure. Therefore, 
a considerable number of experimental studies have 
been conducted over the years to understand the 
potential hazards of these two compounds. Piperazine 
has also been classified and an EU risk assessment 
report has been written. With regard to AMP and 
MDEA few studies are available in the literature data-
bases. In this report we have evaluated the toxicity 
of the amines from single and repeated exposures, 
including their potential to cause mutations, tumors 
and birth defects. The toxicology data have been 
compiled and critically reviewed as far as possible. For 
each amine either the no observed adverse effect level 
(NOAEL) or the lowest observed adverse effect level 
(LOAEL) are indicated. Based on these data we have 
suggested an exposure guideline for the general popu-
lation for each of the amines. 
Monoethanolamine (MEA)
Monoethanolamine (MEA) (CAS number 141-43-5) is 
a liquid at room temperature. It is completely miscible 
with water, with a low volatility and possesses an 
ammoniacal odour. The odour threshold is 5-8 mg/m3. 
MEA is a strong base (pH 12.05 of 0.1N aq. sol.), which 
readily forms salts with inorganic and organic acids. 
The substance is widely used in industry in the produc-
tion of soaps and detergents, as a cleaning and cooling 
agent, as an ingredient in cosmetic formulations, in 
the synthesis of dyestuffs, in rubber accelerators, and 
removal of acids gases from atmospheres, such as 
carbon dioxide from submarines. 
The substance is currently classified as:
Xn; R20/21/22 (Harmful by inhalation, in contact with 
skin and if swallowed) C; R34 (Corrosive, causes burns).
Toxicokinetics and metabolism 
MEA is a normal constituent of the body in both 
animals and humans. It occurs naturally in a group of 
phospholipids known as phosphatides. This group of 
complex lipids is composed of glycerol, two fatty acids, 
and phosphoric acid linked to the hydroxyl group of 
glycerol and a nitrogenous base such as choline or 
MEA (Knaak et al 1997). 
MEA is absorbed following oral administration, inha-
lation, and dermal exposure (Binks et al 1992). Upon 
dermal application the major site for the metabolism 
of MEA is the liver, where it is incorporated into phos-
pholipids. MEA is also distributed to kidneys, lungs, 
brain and heart. However, the bulk of the dose seems 
to remain in the epidermis (Gillner and Loeper 1993). 
Since MEA is a normal constituent in the body, it is also 
found in human urine. The molecule can be deami-
nated, the amine excreted as urea, and the carbon may 
be used as energy source in the body and be oxidized 
fully to carbon dioxide. Whether MEA is excreted 
unchanged or metabolized in the urine, depends prob-
ably on the concentration in the body. This may be due 
to saturation of metabolic pathways and suggests that 
excess levels in the body are not accumulated, but can 
be directly eliminated via the kidneys.
The fate of ethanolamine-1,2-C14 in the intact rat and 
its tissues has been studied (Knaak et al 1997). Most of 
the dose (54%) was found in the liver, spleen, kidneys, 
heart, brain and diaphragm, and 12% was accounted 
for as 14CO2 8 hours after intraperitoneal administra-
tion. The radioactivity in tissues was found distributed 
in lipid, amino acid, organic acid and sugar fractions. 
Approximately 85% of the tissue radioactivity was 
found in the lipid fraction. The liver was shown to be 
the major site for metabolism of MEA followed by the 
heart and brain. 
Experimental toxicology 
Acute toxicity. The acute oral toxicity of MEA has been 
studied in several laboratory animal species and it 
appears to be relative low (Knaak et al 1997). The oral 
dose, after which 50% of the animals died (LD50) in 
rats, was 1.1-2.7 g/kg body weight  (bw). Apparently 
there were no significant sexual or species differences 
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in acute toxicity with respect to MEA. No inhalation 
LC50 values (air concentration after which 50% of 
the animals died) have been reported. However, no 
mortality was registered for rats exposed for 6 hours to 
substantially saturated vapour concentration of MEA 
generated at room temperature or to a combination 
of saturated vapour and mist generated at 170 oC. The 
theoretical saturated vapour concentration of MEA 
at room temperature is 520 ppm (1.3 g/m3). Thus, the 
LC50 seems to be higher than that concentration.  
Subacute, subchronic and chronic toxicity. Repeated oral 
administration to rats for 90 days has indicated a NOAEL 
of 320 mg/kg bw/day (Binks et al 1992). Repeated inha-
lation of more than 160 mg/m3 MEA for periods of 24-90 
days in several species induced behavioural effects and 
degenerative changes in different organs, especially in 
the liver and kidneys (Weeks et al 1960). The animals 
displayed also pronounced clinical signs of skin and 
respiratory irritation, which progressed with time to hair 
loss, severe skin lesions, moist rales and fever in dogs 
and breathing difficulties in rats and guinea pigs (see 
also below). Effects were observed at all exposure levels 
and a NOAEL was not found. Repeated inhalation of as 
low as 30 mg/m3 MEA for 90 days caused behavioural 
effects in dogs (progressive stages of excitation followed 
by depression). Furthermore, rats exposed to 12 mg/
m3 MEA exhibited lethargy after 2-3 weeks exposure 
(Weeks et al 1960). The behavioural changes reported 
for exposed animals may reflect the extreme irritancy 
of the MEA atmospheres employed. Weeks et al (1960) 
reported that MEA was at least 10 times more toxic 
following inhalation than gastrointestinal uptake. There 
are very limited data available on long-term toxicology.
Irritating properties. The most pronounced acute effects 
of MEA in animals are those related to the irritant prop-
erties. MEA can cause burns and necrosis to the skin 
following a 4 hours exposure, also eye irritation and 
irritation of the respiratory tract have been observed 
(Gillner and Loeper 1993). Exposure of rats, dog and 
guinea pig to MEA vapour has been reported to induce 
skin irritation at as low concentration as 12 mg/m3 
(Week et al 1960). The authors indicate, however, that 
this might be due to a direct dermal exposure to MEA 
as vapour condensed onto the surfaces in the expo-
sure chambers. 
Sensitization. No animal studies have assessed the 
skin sensitization potential of MEA (Knaak et al 1997). 
Repeated-insult skin patch testing of human volun-
teers or chemical workers has produced negative 
results. The overall evidence suggests MEA not to be 
allergenic.  
Genotoxicity and carcinogenicity. MEA lacks mutagenic 
potential in Ames bacterial mutagenicity when tested 
in the presence or absence of a metabolic activation 
system with a variety of Salmonella typhimurium tester 
strains developed to identify base-pair substitution 
or framshift mutagens (Knaak et al. 1997).   MEA also 
failed to cause mutations in a test organism that is 
sensitive to oxidative-type mutagens (Escherichia 
coli). Several assays of the potential of MEA to damage 
DNA in a bacterial tester strain (Bacillus subtilis rec 
assay) and to cause chromosomal damage in yeast 
cells (Saccharomyces cerevisiae gene conversion assay) 
have been negative. MEA did not induce chromosome 
damage in rat liver epithelial-type cells. No in vivo 
genotoxicity studies have been reported. Furthermore, 
no data on carcinogenicity have been located.
Reproductive and developmental toxicity. In rats MEA is 
reported to cause significant, dose- dependent intrau-
terine growth retardation, and increases in malforma-
tions and intrauterine deaths after oral administration 
to the dams during the period of organogenesis 
(Mankes 1986). These effects were seen down to the 
lowest dose studied (50 mg/kg bw/day). At this dose 
level no maternal toxicity was seen. The male offspring 
were more severely affected than female pups. In 
another study with rats no effects on organ develop-
ment or fetal weight were observed even at high 
doses (450 mg/kg/day) which caused maternal toxicity 
(Hellwig and Liberacki 1997). Decreased or repressed 
spermatogenesis was seen in guinea pigs exposed to 
MEA vapour at about 190 mg/m3 for 24 days and dogs 
exposed to about 250 mg/m3 for 30 days (Weeks et al 
1960). The significance of this observation is not clear 
as these concentrations resulted in the death of 75% of 
the guinea pigs and one of three dogs exposed. 
Human data
Occupational exposure to MEA mainly occurs by inha-
lation (Gillner and Loeper 1993). The general popula-
tion may also be exposed by dermal contact to MEA 
in cosmetic formulations. The effects on humans are 
related to the primarily irritative local action of MEA. A 
concentration of 5.9% is irritating to human skin. There 
have also been reports of occupational asthma and 
skin sensitization following MEA exposure (Binks et al 
1992). In a study by Sidorov and Timofievskaya (1979) 
increased incidence of liver and gall bladder disease 
and chronic bronchitis in humans at levels as low as 1 
mg/m3 was observed. This study is however criticized 
due to their poor reporting on number of subjects 
and duration of exposure. Similarly chronic hepatitis 
was also found in one subject following an accidental 
high exposure to MEA. This is difficult to evaluate as 
the conditions at the time indicate it was a mixed 
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exposure. The other solvents were not specified and no 
indication of the level of the exposure was given (Binks 
et al 1992).
Occupational exposure limits 
Because of the lack of human data the use of animal 
studies was necessary to make a health-based expo-
sure limit in the occupational environment (SCOEL 
1996). An EU directive from 2006 describes indica-
tive exposure limit values for MEA. The time-weight 
average (TWA) value for 8 hours is 2.5 mg/m3 and the 
short-term exposure limit (15 min) is 7.6 mg/m3. The 8 
hours administrative norm has recently been changed 
to 2.5 mg/m3 in Norway (Arbeidstilsynet 2007).
Health risk evaluation
The study of Weeks et al (1960), establishing a LOAEL 
of 12 mg/m3 air for behavioural effects in rats seems to 
be the best available basis for proposing an exposure 
limit for the population. The same study was also used 
when establishing the occupational exposure limit 
(Arbeidstilsynet 2007). Since this LOAEL value is based 
on an animal experiment, an uncertainty factor has to 
be used. The occupational exposure limit includes an 
uncertainty factor of only 5. However, for the general 
population a factor of 10 is normally applied because 
of extrapolation from animal studies (rat) and another 
factor of 10 for the variability between the individuals 
(in human a population). Use of a LOAEL value instead 
of a NOAEL should affect the size of the uncertainty 
factor by a factor of 3, but as the effects seen here were 
minimal we have decided to use a factor of 2. Further-
more, use of subacute instead of chronic should 
increase the uncertainty factor by 6. All together, this 
infers the uncertainty factor to be 1200. Therefore, we 
suggest that the general population, over time, should 
not be exposed to levels in the air higher than  
10 µg/m3 MEA. 
Piperazine 
All data presented are based on information in the EU 
risk assessment report – piperazine final report, 2005. 
No relevant health effect data on piperazine were 
found in a litterature search from 2005 to 2008.
Piperazine (CAS number 110-85-0) is white or trans-
lucent, and occurs as rhomboid or flake-like crystals 
that are highly hygroscopic at room temperature. It is 
a white mass in water and highly basic with two disso-
ciation constants, pKa1=9.7 and pKa2=5.3. It is used in 
veterinary pharmaceuticals as anthelmintics, i.e., drugs 
that act against infections caused by parasitic worms. 
Formerly, it was also used in human medicine. Other 
industrial uses of piperazine are as hardener for pre-
polymers for glue, in gas washer formulations, as inter-
mediate for urethane catalysts, and as an intermediate 
for a number of pharmaceuticals.
Classification by EU:
Repr. Cat. 3; R62-63 (Possible risk of impaired fertility/
harm to the unborn child)
C; R34 (Corrosive; Causes burns)
R42/43 (May cause sensitisation by inhalation and skin 
contact)
Labelling:
Xn; C
R: 34-42/43-62-63
Toxicokinetics and metabolism
Piperazine is readily absorbed from the gastrointestinal 
tract in pigs, and the major part of the compound is 
excreted as unchanged piperazine during the first 48 
hours. The principal route of excretion of piperazine 
and its metabolites is via urine, with a minor fraction 
recovered from faeces (16%). However, about one forth 
of a single administered oral dose is retained in the 
tissues after 7 days, some of which seems to consist of 
unidentified conversion products. Besides N-mononi-
trosopiperazine, no other metabolites have been iden-
tified. No data on dermal or respiratory uptake have 
been located. Default absorption values of 100% are 
assumed for dermal and inhalation exposure.
In humans the kinetics of the uptake and excretion of 
piperazine and its urinary metabolites appear to be 
roughly similar to that in the pig, but the nature and 
extent of conversion to metabolites remains unknown. 
In the presence of nitrite, the in vivo formation of small 
amounts of nitrosated products from piperazine has 
been demonstrated to occur in the gastrointestinal 
tract of experimental animals as well as in humans.
Experimental toxicology
Acute toxicity
Piperazine has demonstrated a relatively low acute 
toxicity (LD50 1-5 g/kg bw) by the oral, dermal, and 
subcutaneous route of administration to rodents, 
whereas adequate inhalation toxicity data could not 
be located. 
Subchronic and chronic toxicity
Upon repeated dose oral administration to rats and 
dogs, except for some signs of liver toxicity, little 
evidence of systemic toxicity was observed even at 
the highest tested dose. Based on induction of mild 
hepatic involvement in the Beagle dog a NOAEL of 25 
mg/kg bw/day of piperazine base was established. 
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Although inadequately reported, a 90 day study in 
rats indicates an approximate LOAEL of 150 mg/kg 
bw/day based on histopathological changes in liver 
and kidneys. The NOAEL in beagle dog was chosen 
by EMEA (The European Agency for the Evaluation of 
Medical products) as the basis for setting an accept-
able daily intake (ADI) and provisional maximum 
residual levels (MRLs) for the use of piperazine as a 
veterinary anthelmintic in pigs and poultry (EMEA, 
2001a). Adequate chronic bioassays are not available. 
None of the animal experimental studies reported 
neurotoxic effects as a cause for serious concern. 
However, such effects, that occasionally are serious, 
have been well documented in clinical practice, and 
have also been described by veterinarians in rabbits, 
dogs, cats, tigers, horses, the puma, and sea lions, 
but not in rodents. The mechanism of the neurotox-
icity induced by piperazine in mammals is unknown. 
Although it may be assumed that similarly to its action 
in invertebrates, it acts as a neurotransmitter. The 
inability to detect any signs of such toxicity in available 
subacute and subchronic studies is a reason for concern, 
and makes it impossible to establish a LOAEL or NOAEL 
with respect to this important toxicological endpoint. 
It is established beyond doubt that piperazine after 1-7 
administrations induces neurotoxicity in some mamma-
lian species including humans, among which children 
appear to be particularly sensitive. Hence, this end-point 
has not been adequately investigated. 
Irritating and corrosive properties
In rabbits, a 50% aqueous solution of piperazine base 
(i.e., piperazine anhydrate) has strongly irritating 
properties, including induction of skin necrosis. At a 
concentration of 11%, piperazine base may induce 
erythema and marked vesiculation on human skin, 
whereas no effects were observed at a concentration 
< 2.2%. Piperazine base and piperazine hexahydrate 
may cause etching and necrosis of the rabbit eye 
at a concentration of 1-5% and should be regarded 
as corrosive (Carpenter and Smyth, 1946). Existing 
biological data on the corrosive properties of pipera-
zine are corroborated by its high pH in aqueous solu-
tions. Piperazine is currently classified with R34, which 
applies for piperazine base and piperazine hexahy-
drate. No corrosivity is expected for piperazine salts.
Sensitization
Exposure to piperazine and its salts has been demon-
strated to cause allergic dermatitis as well as respira-
tory sensitisation, but no NOAEL can be set as no 
threshold could be deduced from these studies. 
Dermal sensitisation is also shown in the mouse local 
lymph node assay. A cross-sensitisation between piper-
azine and diethylentriamine was observed in guinea 
pigs. It must be concluded that piperazine is a dermal 
and respiratory sensitizing agent. 
Genotoxicity and carcinogenicity
Studies conducted in vitro, as well as in vivo indicate 
that piperazine does not induce point mutations or 
chromosome aberrations (in the Ames test, in a non-
standard study on Saccharomyces cervisiae and in 
Chinese hamster ovary cells). Due to the likelihood of 
exposure to other clastogenic chemicals, the signifi-
cance of the modest increase in micronuclei seen in 
one cohort of exposed workers cannot be ascertained. 
However, nitroso-piperazines that can be formed by 
nitrosation of piperazine in vivo demonstrate clear 
genotoxic properties (in vivo DNA strand breaks and 
mutations).
There are no solid indications of a carcinogenic effect 
of piperazine, neither in animal studies, nor from the 
investigation in humans. However, the supporting 
database is insufficient to permit definite conclu-
sions. The two nitrosated derivatives of piperazine, 
N-mononitroso-piperazine and N,N’-dinitrosopipera-
zine, whereof the first has been identified as a minor 
metabolite of piperazine, have in addition to induce 
mutations in vivo, and also been found to be carcino-
genic in rodents.
Reproductive and developmental toxicity
For reproductive effects based on data from a two 
generation rat study (Wood and Brooks, 1994), a 
NOAEL of 125 mg/kg bw/day and a LOAEL of 300 
mg/kg bw/day piperazine can be established, based 
on reduced pregnancy index, decreased number 
of implantation sites and decreased litter size. The 
decreased litter size is evaluated as the main effect. 
The NOAEL for the adult animals is estimated to be 125 
mg/kg bw/day piperazine base. This NOAEL is based 
on body weight decreases (<10%) at 300 mg/kg bw/
day in the parental males and in the offsprings. 
The developmental toxicity has been investigated 
in rats and rabbits in adequate studies. In rabbits, 
embryotoxic as well as teratogenic effects were elicited 
only at doses that also caused overt signs of toxicity in 
the mother animal (maternal LOAEL/NOAEL, 94/42 mg/
kg bw/day, respectively).
Human data
Acute toxicity
Neurotoxic changes as examined by EEG have been 
reported in 37% of 89 children administered 90-130 
mg/kg/bw piperazine base (two doses during one 
day), corroborated by the proposed function to pipera-
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zine as a neurotransmitter. Since more severe neuro-
toxicity symptoms can appear after exposure to higher 
doses (given during several days), a LOAEL of 110 mg/
kg bw for neurotoxicity in humans after acute expo-
sure is proposed.
Subchronic and chronic toxicity
For previously healthy humans, a LOAEL of 30 mg 
piperazine base/kg bw/day for neurotoxicity has been 
established for a limited treatment period (3-7 days). 
Since there is little information on effects at lower 
doses than the therapeutic dose, the 30 mg/kg bw/day 
dose should rather be regarded as a ‘low OAEL’ than a 
true LOAEL. Based on existing data, a NOAEL cannot be 
established for neurotoxicity induced by piperazine, 
neither in a sensitive animal species nor in humans 
upon long-term exposure. In humans, repeated expo-
sure to piperazine by inhalation may induce chronic 
bronchitis, but no LOAEL or NOAEL can be established 
for this endpoint.
Irritating and corrosive properties
Six occupational exposure scenarios concerning 
production of piperazine flakes and piperazine salts, 
and industrial use of piperazine in syntheses have 
been considered. Worst-case exposure is assumed for 
the scenarios on production and industrial use, by 
using monitored data when available, and otherwise 
modelled values for inhalation exposure and dermal 
exposure.
Sensitization
Exposure to piperazine and its salts has clearly been 
demonstrated to cause asthma in occupational 
settings. No NOAEL can be estimated for respiratory 
sensitisation (asthma). The external worker exposure 
inducing occupational asthma by inhalation has been 
estimated to be up to 8.6 mg/ m3 during normal work 
for an 8-hour day. 
Reproductive and developmental toxicity
There is one case report available, describing the birth 
of a girl with malformed hands and feet as a possible 
result of piperazine exposure of the mother (Keyer and 
Brenner, 1988). The mother was treated orally with 
piperazine adipate (2,100 mg/day or 38 mg/kg/day 
assuming a body weight of 55 kg) during two 7-days 
periods. At birth, both hands and one foot displayed 
malformations. It is difficult to evaluate the possible 
relationship with the piperazine treatment from this 
only case.
Occupational exposure limits 
Commission Directive 2000/39/EC (European Commis-
sion, 2000) establishes a first list of indicative occupa-
tional exposure limit values. The values for piperazine 
concerning vapour and dust are 0.1 mg/m3 for 8-hour 
exposure and 0.3 mg/m3 for short-term exposure 
(based on a study by Hagmar et al., 1982). The list was 
implemented in EU member states 31 December 2001.
Health risk evaluation
For neurotoxicity, a LOAEL in healthy humans of 30 
mg/kg bw/day piperazine base for a limited 3-7 days 
exposure has been established. A NOAEL of 25 mg/
kg bw/day for induction of mild hepatic involvement 
in the Beagle dog has also been established. Further-
more, a LOAEL for inducing occupational asthma after 
inhalation of piperazine has been estimated to be 8.6 
mg/m3 during normal work for an 8-hour day. 
The estimated exposure from human inhalation 
studies of 8.6 mg/m3 will be used in the risk estimation 
below. This is due to the anticipation that the main 
route of exposure of amines for the general population 
will be via inhalation. Exposure to piperazine and its 
salts has clearly been demonstrated to cause asthma 
in occupational settings. No NOAEL can be estimated 
for respiratory sensitisation (asthma). However, the 
external worker exposure by inhalation has been esti-
mated to be up to 8.6 mg/m3 (vapor and dust) during 
normal work for an 8-hour day. For short-term expo-
sure (15 minutes), the concentrations may be twice 
the above mean value. The study by Hagmar et al., 
1982 showed occupational asthma measured at lower 
concentrations than the estimated exposure level 
described above. However, the exposure levels could 
only be roughly estimated and the LOAEL as well as 
NOAEL for asthma induction in this cohort is, therefore, 
associated with too much uncertainty to be brought 
forward to the risk evaluation. 
The exposure indications of amines released to the 
environment is expected to be high and this suggests 
that Piperazine represents a risk for man exposed via 
environment. It is clear that piperazine is a respiratory 
sensitiser and based on the presented data we choose 
the external worker exposure estimated exposure 
value of 8.6 mg/m3 as a LOAEL. For the risk evaluation 
there is considered a need for the use of uncertainty 
factors. A factor of 10 for the variability between the 
individuals in a population is used. Both a factor of 
3 for extrapolation from a LOAEL to a NOAEL and an 
exposure factor for subchronic to chronic of 2 are 
included. In addition a correction factor for work expo-
sure versus lifetime exposure of 2.8. As there are find-
ings of both neurotoxicity, mild hepatic toxicity and 
reproductional effects in human and animal studies, 
we have also included a factor of 10 for severe health 
effects (neurotoxicity). Together the uncertainty factor 
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will be 1680. Therefore, we suggest that the general 
population should not, over time, be exposed to 
higher levels than 5 µg/m3 piperazine base.
Aminomethylpropanol (AMP)
The report of AMP is mainly based on the “Final report 
on the safety assessment of aminomethylpropanol and 
aminomethylpropanediol” in the Journal of the Amer-
ican College of Toxicology Volume 9 Number 2 1990 
and an IUCLID report from 2000. Most of the studies 
referred to in these reports are unpublished and have 
therefore not been available to us. Hence, this report is 
based on previous evaluations performed by others. In 
general, data for AMP were limited. 
AMP is also known as isobutanolamine and 2-amino-
2-methyl-1-propanol (CAS number 124-68-5). AMP is 
either a colourless liquid or a white crystalline solid. 
Since the melting point is slightly above room temper-
ature AMP may also appear as a paste. In liquid form 
AMP has a slight amine-like odour, while in solid form 
it is odourless. AMP is miscible with water, soluble in 
alcohols, slightly soluble in aromatic hydrocarbons, 
and insoluble in aliphatic hydrocarbons (CIR 1990). The 
pKa for AMP is 9.7 at 25˚C (IUCLID 2000). 
AMP is widely used in cosmetics, as an emulsifying 
agent, as a pH adjuster and to regulate the solubility, 
flexibility and tackiness in cosmetic creams, lotions, 
soaps, shampoos, shaving creams, hair sprays, hair 
dyes and colours and more. The content of AMP in 
cosmetic is most commonly in the range of 0.1% - 1% 
with a few products containing more than 1% AMP. In 
non-cosmetic products AMP has been used in leather 
dressings, cleaning compounds and polishes, insec-
ticides, paints, antibacterial agent and as an indirect 
food additive. Products containing AMP may come in 
contact with the skin, eyes and mucous membranes. 
The exposure may be temporary or prolonged and 
for many products the exposure is repeatedly over a 
period of time (CIR 1990).
The substance is currently classified as:
Xi; R36/38 (Irritating to eyes and skin)
Toxicokinetics and metabolism
AMP has been found to interfere with the formation 
of free fatty acids from lipids. AMP injected intraperi-
toneally in rats fed a choline-deficient diet (choline 
deficiency inhibits “fat removal”) caused inhibited 
fat catabolism and increased amount of hepatic lipid 
and an increased fat content of the liver. The authors 
suggested that AMP, or metabolites of AMP, might 
become incorporated into phospholipids and inhibit 
the incorporation of ethanolamine which will result 
in a reduced conversion of choline and consequently 
increase the amount of lipids in the liver (CIR 1990). 
AMP is rapidly and completely absorbed from the 
gastrointestinal tract in rats (Saghir et al. 2008). The 
maximal blood concentration was reached within 
15 minutes of dosing and only 3-4% of the adminis-
trated dose was found in the tissues 168 hours post 
dosing. The highest dose level was found in the liver 
and kidney. Between ~ 90% of the AMP dose was 
eliminated by urine and most (~75%) within the 
first 48 hours. Faecal elimination accounted for only 
3-10%. The elimination of AMP after oral administra-
tion occurred via two phases. Most of it was rapidly 
eliminated (α elimination). The level in blood was 
reduced by 7-9 folds in a 4-hour period. Thereafter the 
elimination was slower, which is suggested to include 
elimination of AMP that has been incorporated into 
phospholipids and other cellular fractions. AMP is 
excreted unchanged. No metabolites have been found 
in blood or excreta which are suggested to be due to 
steric hindrance and a fairly stable structure of AMP 
(Saghir et al 2008).  
Dermal absorption of AMP in rats has been found 
to be relatively high, but slower compared to oral 
administration. Saghir et al. found that the total dermal 
absorption of AMP was 42% which included ~ 8% of 
the dose remaining at the application site 162 hours 
after washing. Less than 1% of the dose remained 
in the stratum corneum. Approximately 6% of the 
applied dose was found in the various tissues with a 
distribution similarly to that of the orally dosed rats. 
Most of the administrated dose was eliminated by the 
urine (43%) (Saghir et al 2008).    
Experimental toxicology
Acute toxicity 
The LD50 for rats and mice were 2.9 and 2.15 g/kg bw, 
respectively (Anon 2007; CIR 1990; IUCLID 2000). In 
an acute toxicity study in rats AMP caused lesions in 
the liver, kidneys, spleen and lungs at LD50 dose. In 
another acute oral study in rats, no effects caused by 
AMP were found. In a study with monkeys AMP solu-
tion had toxic effects on the gastrointestinal tract, but 
the effect was most likely due to the alkalinity (pH>11) 
of the AMP solution (CIR 1990). 
In the IUCLID dataset dermal LD50 was found to be > 
2 g/kg bw in rabbits. The study followed GLP, but no 
further information was given (IUCLID 2000).
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The LD50 for mice given AMP intraperitoneally was 
found to be 325 mg/kg bw. The study is from 1955 and 
does not follow GLP (IUCLID 2000).
No LC50 was noted in the IUCLID dataset. In the CIR 
report on AMP three acute inhalation studies with 
cosmetic formulations containing AMP and one 
inhalation study with AMP in alcohol and propellant 
was described. The highest concentration tested was 
200 mg/l of a 2.5% AMP solution (one hour exposure 
time). By necropsy one animal in two separate studies 
showed abnormalities in the lungs. In a separate study 
two females had tremors upon removal from the test 
chamber. The rats appeared normal after 24 hours. No 
significant histological changes were observed. The CIR 
1990 report concluded that the observed effects were 
not related to treatment and that the results of the 
studies indicated that AMP was nontoxic by inhalation. 
Subacute, subchronic and chronic toxicity  
In a 28-days range finding study one beagle dog of 
each sex were given AMP in the diet at concentra-
tions of 600, 1800, 5400 and 16200 mg/kg. In the 
three highest doses dogs had frequent soft stools 
and diarrhoea. Both dogs of the highest dose group 
had marked weight loss, anorexia and dry noses and 
mouths. Damage to the liver and reduced liver weight 
was dose-dependent (CIR 1990).  
In an eight weeks study 10 mice of each sex were given 
AMP in the diet at concentrations of 200 to 3200 mg/
kg. At the end of the experiment, all mice appeared 
normal. No gross or microscopic lesions were found in 
the liver. NOAEL was set to > 3200 mg/kg (Anon 2007; 
CIR 1990).  
In a similar study with rats the same test protocol as 
in the mouse study was used, except that the dietary 
concentration were 1000, 2000, 4000, 8000 and 16000 
mg/kg. The rats given the highest dose were emaci-
ated and had rough hair coat, small skin lesions and 
loss of hair. Two females in the highest dose group 
died before the end of the study. Alopecia and focal 
skin erosions were observed in rats given the highest 
dose. Hepatocyte vaculation was observed in rats at 
all doses and was considered compound-induced. The 
LOAEL was suggested to be 1000 mg/kg (Anon 2007; 
CIR 1990).  In a 90-days study with rats AMP solutions 
with pH 7 and 11 were tested. It was concluded that 
the mortality observed was caused by the alkalinity 
of the solution and not by AMP per se (CIR 1990).  In a 
90-days study four male and four female beagle dogs 
were fed diets containing 0.63, 15.0, or 62.5 mg AMP/
kg bw (pH 7). Only the dogs of the high-dose group 
did not gain weight during the study. Also liver and 
liver/body weights ratios were increased and tan 
and mottled livers were observed by necropsy in the 
high-dose group. Vacuolisations and lipid deposits in 
the liver, and bile duct hyperplasia were observed by 
microscopic examination in all dogs at the high dose 
and one dog at the mid dose (CIR 1990).  Based on 
liver effects the NOAEL was set to 0.63 mg/kg bw/day. 
However, in a one year dog study reported in IUCLID 
(2000) the NOAEL was considered to be much higher 
(≥ 100 mg/kg bw). 
Generally it was not noted whether the concentrations 
of AMP used in the inhalation studies were the highest 
attainable or not. No per cent inhalable aerosols were 
given and the exposure time and strategy varied. Since 
most of these studies are performed with cosmetic 
solutions containing AMP it is also difficult to interpret 
whether the observed effects are caused by AMP alone 
or by the combination of AMP in the solution. 
An inhalation study was preformed with hair spray 
containing 0.58% AMP solution. Rats were exposed to 
the atmosphere containing 200 mg/l of the hair spray 
(1 hour/day, 5 days per week for 2 weeks). No gross 
changes were noted at necropsy, and weight gains 
were comparable between the test animals and the 
control group (CIR 1990).
Three inhalation 90-days studies have been performed; 
one study with rats and two with monkeys. In all 
studies pump hair spray containing AMP was used. 
Rats exposed to 0.44% AMP solution in a concentra-
tion of 0.23 μg/l had statistically significant hemato-
logic changes compared with the control. However, 
the laboratory claimed that the changes were within 
the normal range for this species. It was observed 
that female rats had significantly decreased uterine 
and lung weights and increased heart- and liver-to-
body weight ratio. No treatment-related microscopic 
changes were observed in the evaluated tissues. In 
a study where monkeys were exposed to 6.06 and 
6.63 μg/l of a hair spray containing 0.40% AMP, no 
compound-related alterations of the tissues were 
found upon histopathological examination. However, 
reduced weight gain during the study was observed. 
In the second study monkeys were exposed one hour 
daily to 2.7 or 27 μg/l of a hair spray containing 0.21% 
AMP. Some histopathologic changes in the pulmo-
nary tissues and pulmonary alveolitis were noted in 
the high-dose group. A slight to moderate increase of 
hepatocellular lipids were observed in all animals (CIR 
1990).  
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Irritation
AMP has been classified as an irritant to eyes and skin 
(IUCLID, 2000). In a data sheet for AMP coughing and 
sore throat were also noted (IPCS 2002). In the CIR of 
1990 several dermal irritation studies are described. 
Only in two of the studies AMP caused mild irritating 
to the skin. Cosmetic formulations containing 0.22-
0.56% AMP were used. Also several eye irritation 
studies were described. AMP was given in different 
formulations containing 0.22-0.58% with various expo-
sure strategies. In some of the studies AMP caused eye 
irritation to some animals. In one study the irritation 
observed was classified as a mild irritation according 
to the Draize classification system (CIR 1990; IUCLID 
2000).
Sensitisation 
AMP was tested in a Bhuler test (1982, GLP) and was 
not found to have sensitisation potential (IUCLID 
2000). 
Genotoxicity and carcinogenicity 
A plate assay mutagenicity test was performed using 
AMP and Saccharomyces cerevisiae strain D4 and 
Salmonella typhimurium strains TA1535, 1537, 1538, 
98 and 100. The results indicated that AMP was not 
mutagenic, with and without metabolic activation (CIR 
1990; IUCLID 2000). AMP was tested in a one year study 
with dogs. No evidence of any preneoplastic lesions 
was found and the data suggest that AMP is not carci-
nogenic (Anon 2007).
Reproductive and developmental toxicity 
In a recent rat reproductive/developmental screening 
study, the HCl salt of AMP was found to be fetotoxic 
in rats. The study was performed in 2005 according to 
OECD guideline 421. Male and female rats were fed 
diets containing 0 (control), 100, 300 or 1000 mg AMP-
hydrogen chloride/kg bw/day. Evidence of complete 
litter resorption (100% post-implantation loss) was 
seen at 1000 mg/kg bw/day, and significant resorp-
tions were seen at 300 mg/kg bw/day. In rats given 
300 mg/kg bw/day decreased litter size, increased pup 
body weight and decreased gestation body and body 
weight gain were observed. The NOAEL for systemic 
toxicity for males (parent generation) was 100 mg/kg 
bw/day. NOAEL for females (parent generation) could 
not be established due to liver effects in the lowest 
dose group. The NOAEL for reproductive toxicity was 
considered to be 100 mg/kg bw/day (Anon 2007). 
In a developmental study performed in 2006 in accord-
ance with OECD guideline 414, female rats were 
dermally exposed six hour daily to 0, 30, 100 or 300 
mg AMP/kg bw/day during gestation days (day 6 post 
mating to day 20). Dermal findings at 30 and 100 mg/
kg bw/day were not considered adverse. NOAEL for 
maternal toxicity based on dermal effects was 100 mg/
kg bw/day. AMP did not cause any systemic or devel-
opmental toxicity at any dose level tested. The NOAEL 
for developmental toxicity was considered to be 300 
mg/kg bw/day (Anon 2007).
Human data
Skin irritation and sensitisation potential has been 
examined in humans. Fifteen persons tested a 
cosmetic formulation containing 0.22% AMP using a 
single insult occlusive patch test. One person had an 
equivocal reaction and it was concluded that AMP had 
a negligible primary skin irritation potential (CIR 1990). 
In a sensitisation study 97 persons were exposed to 
different AMP formulations for three weeks. Thirteen 
persons had weak reactions during induction phase 
and one person had a weak reaction after challenge. 
This result supports the negative finding in the Bhuler 
test from 1982 indicating that AMP is not a sensitizer. 
Health risk evaluation
To suggest a maximal exposure level for the general 
population two 90-days studies are possible to use. 
Both studies have limitations and no one is optimal. In 
the oral dog study, there are uncertainties of the dose 
given, while in an inhalation study with monkeys, AMP 
was given in hair spray which may influence the effect 
of AMP. 
In the 90-days inhalation study, monkeys were 
exposed one hour daily to 2.7 or 27 μg/l of hair spray 
containing 0.21% AMP.  Effect on the target organ 
(liver) was observed at both dose levels. The LOAEL was 
set at 2.7 μg hair spray/l which compares to 0.57 mg 
AMP/m3air. An uncertainty factor of 5 for the variability 
between species (monkeys to humans), an uncertainty 
factor of 10 for variations in the human population and 
an uncertainty factor of 2 for using a subchronic study 
instead of a chronic study were included. Together the 
uncertainty factor is 100. Based on this, it is suggested 
that the general population, over time, should not be 
exposed to higher levels of AMP in the air than 6 μg/
m3. We have also calculated a maximal exposure level 
based on a 90-days beagle dog feed study. Unfortu-
nately this study is unpublished and it is incomplete 
referred to in the report (CIR 1990). However, the data 
indicate that if the maximal exposure level for the 
general population is calculated based on the dog 
study, the level will be higher than 6 μg/m3. Occupa-
tional exposure limits has not been found for AMP.
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Methyldiethanolamine (MDEA)
Methyldiethanolamine (MDEA) (CAS number 105-59-9) 
is a liquid at room temperature with an ammonia-like 
odour. It is completely miscible with water and has a 
low volatility (vapour pressure 0.001 torr, 25 ºC). MDEA 
is used e.g. as a gas treating agent for absorption and 
removal of H2S and CO2, a urethane catalyst, a textile 
softener, an epoxy curing agent and in pH control. 
The substance is currently classified as:
 Xi; R36  (Irritating to eyes) 
Toxicokinetics and metabolism 
The toxicokinetics of radiolabeled MDEA was studied in 
rats after intravenous (50 and 500 mg/kg bw) and cuta-
neous (500 mg/kg bw) dosing (Leung HW et al 1996). 
MDEA was readily absorbed following dermal applica-
tion. The absorption was 17 – 21% and 41 – 50% after 
6 and 72 hours of contact, respectively. Once absorbed 
from the skin surface, MDEA appeared to be seques-
tered in the skin matrix as evidenced by its delayed 
and steady release into the bloodstream. The highest 
concentrations of radiolabel were found in the liver and 
kidneys. Elimination was primarily through the urine, 
with an excretion half-life in excess of 30 hours after 
dermal application. MDEA was extensively metabolized 
at lower doses. However, nonlinear kinetic behaviour 
following intravenous administration of 500 mg/kg bw 
suggests saturation of metabolism at high doses. 
Leung et al (1996) hypothesise that MDEA, like 
diethanolamine (DEA), could be incorporated into 
membrane phospholipids to form aberrant sphingo-
myelins by following the biosynthetic route common 
to ethanolamine. This may explain in part the tempo-
rary storage in the skin and the delayed appearance of 
radioactivity in blood. 
Experimental toxicology
Acute toxicity 
A report on acute toxicity and primary irritation of 
5 alkylalkanolamines, including MDEA has been 
published (Ballantyne and Leung, 1996). In this report 
the oral LD50 for Sprague-Dawley rats was found to be 
1.9 g/kg bw (1.87 ml/kg bw, gavage). There were no 
significant differences between males and females. 
Dermal LD50s were 10.2 g/kg bw (9.85 ml/kg bw) and 
11.34 g/kg bw (10.90 ml/kg bw) in a 24 hour study in 
male and female rabbits, respectively. Dermal effects 
included moderate to severe erythema and edema 
with ecchymoses, necrosis, and ulceration. These 
effects persisted and progressed to local desquama-
tion, alopecia, and scarring by the end of the 14 days 
observation period. Necropsy of animals that died 
revealed dark red mottled lungs, dark red livers, and 
mottled kidneys. 
Rats were exposed to a saturated vapour atmosphere 
for 6 hours. No mortalities and no significant signs of 
toxicity were reported. 
In addition, several unpublished acute toxicity studies 
are mentioned in IUCLID (2000). The LD50-values cited 
support the conclusions that MDEA is of relatively low 
acute oral and percutaneous toxicity. Furthermore, 
unpublished mice studies with intraperitoneal exposure 
resulted in LD50-values between 500 and 666 mg/kg bw.
Irritating properties 
MDEA was found to be mildly irritating to the skin 
(502 mg or 500 μl) and to the eyes (5 μl) of rabbits 
(Ballantyne and Leung, 1996). Application to the 
skin for 4 hours produced mild erythema and edema 
(lasting about two days) accompanied by a few scat-
tered ecchymoses. In the eye, a slight to moderate 
conjunctival hyperemia and chemosis was observed 
and resolved itself within three days. A slight corneal 
opacity was observed at 24-hours post-treatment in 
one of six rabbits. 
Several rabbit dermal and eye irritation studies are 
cited in IUCLID (2000) reporting effects ranging from 
non-irritating to moderately irritating to skin and from 
moderately irritating to irritating to eyes.
Sensitization 
The skin sensitization potential of 4 alkylalkanolamines, 
including MDEA, has been tested in the guinea pig 
maximization assay (Leung and Blaszcak, 1998). MDEA 
was found to be irritating to skin in an undiluted form, 
but did not induce a sensitization response.
Subacute, subchronic and chronic toxicity
Repeated-dose studies (2 short-term and 1 subchronic) 
investigating local and systemic toxicity of dermally 
applied MDEA in rats are reported by Werley et al, 
1997. The first short-term study exposed rats to 0, 260, 
1040, or 2080 mg/kg bw/day of undiluted MDEA for 
9 days, 6 hours/day. Apparently due to local toxicity 
and effects on body weight, a second short-term 
study was performed with doses of 0, 100, 500 or 750 
mg/kg bw/day of aqueous dilutions of MDEA for 9 
days, 6 hours/day. In the subchronic study, rats were 
dosed with 0, 100, 250 and 750 mg/kg bw/day of an 
aqueous dilution of MDEA (5 days/week, 6 hours/
day over 13 weeks).These repeated dose studies 
resulted in dose/concentration-related skin irritation, 
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and slight changes in weight gain, adrenals gland 
weight, hematological and clinical chemistry changes. 
Histopathological findings were limited to treated skin. 
According to Werley et al, 1997 the highest dose in the 
sub-chronic study (750 mg/kg bw/day) did not induce 
adverse systemic toxicity and can thus be considered 
a systemic “no observed adverse effect level” (NOAEL), 
whereas local skin irritation was seen from doses 
exceeding 100 mg/kg bw (equivalent to a concentra-
tion of 100 mg/ml; 10% solution). However, the hema-
tological and clinical observations for the subchronic 
study were not provided in the article. In addition, it 
is not clear whether histopathological examinations 
of presumed target organs (liver and kidneys) were 
performed.
No repeated dose study with a non-dermal exposure 
route, and no chronic toxicity study have been found 
in the literature search.
Genotoxicity
MDEA was non-genotoxic when tested in the pres-
ence and absence of a metabolic activation system in 
Salmonella typhimurium strains TA98, TA100, TA1535, 
and TA1537 and/or TA97 (Zeiger et al., 1987). A more 
recent genotoxicity study has been performed in 
which several genotoxicity assays were used. In this 
study, MDEA did not induce reproducible, significant or 
dose-related increases in the frequencies of mutations, 
sister chromatid exchanges or micronuclei (Leung and 
Ballantyne, 1997). Some additional in vitro genotox-
icity studies are mentioned in IUCLID (2000). Together 
these results indicate that MDEA is not genotoxic. 
Carcinogenicity
No carcinogenicity or chronic toxicity studies with 
MDEA have been found. Although MDEA is not consid-
ered genotoxic, the structurally similar substance 
diethanolamine (DEA) has been reported to induce 
tumours in mice. Whether MDEA has a carcino-
genic potential via a non-genotoxic mechanism, is a 
possibility which should therefore not be excluded. 
Non-genotoxic carcinogens are assumed to have an 
exposure threshold, below which there is generally no 
reason for concern. 
The following discussion about the mechanism of 
the carcinogenicity of DEA is partly based on the 
“Report on carcinogens. Background document for 
diethanolamine”, prepared for the National toxicology 
program in 2002. DEA, like MDEA, is not genotoxic, 
but induces liver and kidney tumours in B6C3F1 mice. 
However, DEA was not carcinogenic in Fisher 344 rats 
or in a transgenic mouse strain (Tg·AC). As DEA and 
MDEA are very similar substances and MDEA is prob-
ably formed during the metabolism of DEA it can not be 
excluded that MDEA has carcinogenic properties. Poten-
tial mechanisms of DEA induced carcinogenicity include 
its conversion to a carcinogenic nitrosamine, N-nitroso-
diethanolamine (NDELA), which occurred in vivo in rats 
simultaneously administered DEA dermally and nitrite 
orally. However, it is questionable whether the metabo-
lite NDELA explains the hepatocarcinogenisity observed 
in B6C3F1 mice. The second proposed mechanism 
involves the displacement of ethanolamine by DEA in 
phospholipids, an effect that may result in a reduced 
endogenous production of choline. Observations on 
the effects of DEA on choline metabolism support the 
proposal that DEA-induced hepatocarcinogenesis may 
be related to choline deficiency. 
Reproductive and developmental toxicity 
No fertility study has been identified.
One developmental study has been found. In this 
study rats were exposed via the dermal route to 
aqueous dilutions of MDEA (0, 250, 500, and 1000 mg/
kg bw/day, 6 hours/day during gestation days 6 to 15). 
No adverse effects on any gestational parameter or 
increase in the incidence of malformations or varia-
tions were reported. No differences in maternal body 
weight, gestational weight gain, food consumption or 
liver, kidney, or gravid uterine weight were observed 
at any dose group. Maternal toxicity was apparent as a 
mild anaemia in dams at the 750 and 1000 mg/kg bw/
day dose group. Skin irritation occurred at the 1000 
mg/kg bw/day, and increased in severity with time. The 
NOAELs for maternal toxicity and embryofetal toxicity 
and teratogenicity were estimated at 250 and at or 
above 1000 mg/kg bw/day, respectively (Leung and 
Ballantyne, 1998).
Human data
Alkanolamines, including MDEA, are often added 
as borates to metal-working fluids (MWFs). 
Alkanolamines may contribute to irritation as well 
as allergic contact dermatitis in workers from MWFs. 
A study examining responses in dermatitis patients 
to patch testing to components of MWFs, including 
MDEA has been published (Geier et al, 2003). Seven 
of 233 patients reacted positively and one of these 
patients had a reaction to MDEA. The authors state that 
the importance of MDEA as a MWF allergen remains to 
be established.
Occupational exposure limits 
Occupational exposure limits exist for several 
alkanolamines, but has not been found for MDEA. An 
internal company limit value of 10 ppm (approximately 
49 mg/m3) was given in IUCLID (ICI C&P France SA, 
IUCLID 2000).
 16  Rapport 2009:3 • Folkehelseinstituttet
Health risk evaluation
The available studies indicate local irritation of skin and 
eyes following exposure to MDEA. In the subchronic, 
dermal study it is indicated that irritation occurs at 
concentrations higher than 10%. However, eye irrita-
tion seems to be more severe than skin irritation and 
may thus be present at lower concentrations of MDEA. 
MDEA is likely to be irritating also to the respiratory 
tract. However, there is very little information on the 
inhalation toxicity of MDEA. It is important that the 
concentration of MDEA in air is well below levels prob-
able to induce respiratory irritation.
The current health risk evaluation of systemic toxicity 
is based on the toxic effects seen in the repeated dose 
toxicity studies. The lowest systemic NOAEL (dermal 
dose) identified was 250 mg/kg bw/day, resulting in 
mild anaemia in dams in the developmental study. In 
order to suggest a safe ambient air level with regard to 
systemic toxicity we have performed an extrapolation 
from the dermal dose to an internal body dose. The 
concentration in air that will result in a similar internal 
dose was then calculated and appropriate uncertainty 
factors were applied. For the conversion of the dermal 
NOAEL to an internal dose a 17% absorption value was 
used resulting in an internal NOAEL of 42.5 mg/kg bw/
day. A human inhalation volume of 25 m3/24 hours 
(light activity) and 70 kg bw was used to calculate 
the air concentration that may give rise to an internal 
exposure of 42.5 mg/kg bw/day, assuming 100% 
absorption of MDEA via the respiratory tract. An uncer-
tainty factor of 1000 was used to account for intra- and 
interspecies variations (100), as well as for the extrapo-
lation from a 7 day study to the chronic situation (10). 
Based on the above mentioned systemic effects, we 
suggest that the general population, over time, should 
not be exposed to higher ambient air levels of MDEA 
than 120 µg/m3. However, some alkanolamines may 
have a carcinogenic potential as has been reported 
for DEA. Since there were no chronic repeated dose 
studies for MDEA available and the possible nitro-
samines formed are not yet identified, this endpoint 
cannot be properly evaluated at the present time. 
Furthermore, there are no fertility studies available.   
Concluding remarks for the amines
The toxicity studies of the amines, MEA, piperazine, 
AMP and MDEA, have been evaluated. Among these 
amines piperazine has been through the most thor-
ough evaluation and classification in the EU system. 
There are several experimental studies available on 
MEA, but the majority was performed during 1960 
and -70. For AMP and MDEA the toxicological data are 
generally sparse and good quality inhalation studies 
are lacking. 
All the amines seem to be irritative, but only pipera-
zine is reported to be sensitizing. For piperazine and 
MEA there are indications of reproductive and devel-
opmental toxicity. In addition data from one study 
suggests similar effects of AMP, but this has to be 
confirmed by other studies. None of the amines have 
been reported to be carcinogenic, but this should also 
be evaluated further with additional studies.    
The suggested exposure guidelines for the amines 
are based on the available literature; particularly for 
AMP and MDEA there are few high quality studies. The 
guidelines presented here should therefore be used 
as an indication and not as limit values for safety. The 
uncertainty factors were chosen in accordance with 
EU guidelines. Furthermore, use of more than one 
amine infers that the exposure guidelines should be 
evaluated again, since the amines seem to have similar 
adverse effects and might therefore also show additive 
or synergistic effects.
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In this part of the report the potential health hazards 
of different possible degradation products of the 
four amines; monoethanolamine (MEA), piperazine, 
aminomethylpropanol (AMP) and methyldieth-
anolamine (MDEA) are discussed. The choice of rele-
vant degradation products for this hazard assessment 
is based on the report from the Chemical Institute, 
University of Oslo. The toxicological data is lacking for 
many of the specific compounds. Therefore available 
data for similar compounds belonging to the same 
chemical group were evaluated. A general discussion 
of these data and data gaps follows below. 
Nitrosamines
Nitrosamines (N-nitrosamines) are a large and diverse 
family of synthetic and naturally occurring compounds 
having the general formula (R1)(R2) N-N=O, where R1 
and R2 can be an alkyl or aryl group. Nitrosamines are 
typically liquids, oils, or volatile solids. Nitrosamines 
occur in the diet, in certain occupational settings, 
through use of tobacco, cosmetics, pharmaceu-
tical products and agricultural chemicals. Nearly all 
commercially available alkylamines are generally 
contaminated by small quantities of their corre-
sponding N-nitroso analogues. Factories involved 
either in the production or in the use of amines might 
be a source of nitrosamine pollution (Tricker et al 
1989). 
Classification
N-nitrosodimethylamine; dimethylnitrosamine (CAS-no 
62-75-9) is currently classified as: Cancer2; R45T+; R26T; 
R25-48/25N; R51-53
Exposure and metabolism
Human exposures to nitrosamines can occur via four 
main routes; 1) internal nitrosation of precursors 2) 
ingestion 3) inhalation 4) dermal contact. Nitrosamines 
may be formed in the body from nitrosation of amines 
via an acid- or bacterial catalyzed reaction with nitrite, 
or by reaction with products of nitrogen oxide gener-
ated during inflammation and infection. Because a 
variety of amines and reaction conditions are possible, 
there may be hundreds of nitrosamines. The large 
number of exposure sources, including formation in 
the body, results in a complicated matrix of total nitro-
samine exposure. 
The metabolic activation of nitrosamines initially 
involves the enzymatic hydroxylation of the carbon 
atom immediately adjacent to the N-nitroso group by 
members of the cytochrome P-450 enzyme family. This 
oxidation results in an unstable product that rapidly 
decomposes to an aldehyde and a diazohydroxide. 
The latter dissociates to a diazonium hydroxide and 
ultimately to a carbonium ion. The diazohydroxide 
and subsequent intermediates are highly electrophilic. 
Their major reaction is with water yielding an alcohol, 
but they also react with DNA to produce a variety of 
alkylated DNA bases. Detoxification by denitrosation 
competes with this metabolic activation process. The 
denitrosation is also catalyzed by cytochrome P-450 
and results ultimately in the production of nitrite, an 
aldehyde, and a primary amine. The metabolism of the 
short chain nitrosoalkylamines seem reasonable well 
understood, but the biotransformation and metabolic 
fate of the higher members of the homologous series 
need further elucidation.    
Experimental toxicology
Acute toxicity
The potency of nitrosamines in causing acute tissue 
injury and death varies considerably (Shank 1975). 
Acute toxicities of nitrosamines in adult rats expressed 
as a single oral dose, after which 50% of the animals 
died (LD50) range from about 20 mg/kg bw to more 
than 5000 mg/kg bw, with many compounds having 
a LD50 between 150 and 500 mg/kg bw. In general, 
these compounds appear to exhibit a low to moderate 
acute toxicity. Structure and molecular weight play a 
role in determining the acute lethal toxicity. It seems 
that acute toxicity decreases with decreasing chain 
length of nitrosodialkylamines. Cyclic nitrosamines 
such as N-nitrosohexamethyleneimine and N-nitro-
somorpholine are also acutely toxic. The liver appears 
to be the target organ, and liver injury is a common 
result of acute toxicity for a number of nitrosamines. 
The histopathology of N-nitrosodimethylamine 
(NDMA) and N-nitrosodiethylamine (NDEA) acute 
Health effects of possible degradation products  
of amines relevant for the CO2 capture
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poisoning has been well studied. Unfortunately, this 
is not true for most other N-nitroso compounds. 
Detailed studies of the acute toxicity of the N-nitroso 
compunds, as a class, have not been common 
because the striking carcinogenicity of many of these 
compounds has commanded such intense interest 
(Olajos and Coulston 1978).
Mutagenicity
As alkylating agents, N-nitroso compounds are 
extremely potent point mutagens in addition to 
producing chromosome breaks and aberrations (Olajos 
& Coulston 1978). Nitrosamines can induce mutations 
in Drasophilia, but not in microorganisms. They appear 
to require metabolic activation by mammalian enzyme 
systems before they can exert a mutagenic effect. The 
ability of metabolizing enzymes (NADPH-dependent 
microsomal) to form mutagenic compounds from 
nitrosodialkylamines has been demonstrated by 
numerous investigators. NDMA is a model compound, 
shown to induce gene and chromosomal mutations, as 
well as DNA damage, in vivo and in vitro (Olajos & Coul-
ston 1978). Induction of mutagenesis by nitrosamines 
has been reported for various nitrosodialkyl (aryl)-
amines, substituted nitrosodialkylamines and various 
cyclic nitrosamines.
Carcinogenicity
The carcinogenic potential of NDMA in rats was first 
demonstrated in 1956 (Magee and Barnes 1956). Since 
then nitrosamines have been studied extensively in 
laboratory animals. Approximately 90% of the 300 
tested nitrosamines have shown carcinogenic effects in 
bioassay and laboratory animals. Of the approximately 
40 animal species tested, none were resistant (Brown 
1999). Effects of nitrosamines have been demonstrated 
in 29 organs. Tissues affected appear to depend upon 
the structure of the compound, the dosage, the route 
of administration, and the animal species. Changes in 
the alkyl chain have elicited different tumour types. In 
general, the predominant sites of tumour formation 
include the esophagus, kidney, liver, urinary bladder, 
nasal cavities, brain and nervous system, oral cavity, 
stomach, gut, pancreas, hematopoetic system, lungs, 
heart and skin (Olajos and Coulston 1978; Verna et al. 
1996). Studies have shown that the optimal condi-
tions for nitrosamine tumour induction occur via 
exposure to small amounts of the chemical over long 
periods of time. Nitrosamines appear also to induce 
neoplasms transplacentally. Both diethylnitrosamin 
and N-nitrosoethylurea have been reported to induce 
tumors in the off-springs several months after treat-
ment of the pregnant rats (Shank 1975). Inhalation 
studies concerning nitrosamines are limited, however, 
tumours of the nasal cavity and other neoplasms in 
experimental animals have been reported.
It has been reported that one of the amines relevant 
for the CO2 capture, piperazine, can be metabolized by 
microorganisms in the gastrointestinal track to nitrosa-
mines. In the presence of nitrite, the in vivo formation 
of small amounts of nitrosated products from pipera-
zine has been demonstrated to occur in experimental 
animals, as well as in humans. The two nitrosated 
derivatives of piperazine, N-mononitrosopiperazine 
(NPZ) and N,N’-dinitrosopiperazine (DNPZ) have been 
found to be carcinogenic in rodents. Administration of 
NPZ to rats in the drinking water at 400 and 800 mg/l, 
corresponding to a daily average dose of about 27 and 
54 mg/kg bw, induced a clear dose response relation-
ship with respect to tumors in the nasal cavity.
Teratogenicity
 N-nitroso compounds can also be potent teratogens. 
When N-nitrosoethylurea was given to rats before the 
12th day of pregnancy, the compound was not carcino-
genic, but it was a powerful teratogen (Shank 1975). 
Human data 
Acute toxicity
Several case studies have indicated liver injury in 
humans from exposure to NDMA. Both acute liver 
toxicity, liver necrosis and liver damage have been 
reported. Other acute effects of nitrosamines include 
irritation of eyes, lungs and skin, and also vomiting, 
lung damage and convulsions (Brown 1999).
Carcinogenicity
Most nitrosamines are suspected to be human carcino-
gens, but direct causal associations have not yet  been 
found. The suspected mechanism of carcinogenesis 
is that nitrosamines from endogenous or exogenous 
sources are rapidly metabolized after absorption to 
reactive intermediates that can covalently bind to 
macromolecules (DNA), initiating the carcinogenetic 
process. It is generally believed that the carbonium 
ion is the carcinogenic species that reacts with nucleic 
acids to form adducts. Studies have shown that human 
liver tissue appears to metabolize nitrosamines in a 
way similar to that of rodent liver tissue. Experimental 
animal studies have demonstrated DNA adduct 
formation similar to that observed in human studies 
involving nitrosamines. Although a causal association 
has not been firmly established, there is circumstan-
tial evidence that nitrosamines could cause cancer in 
humans (Olajos and Coulston 1978; Verna et al. 1996).
Evidence for cancer excess in industrial populations 
where nitrosamines are known to occur indicates 
involvement of these chemicals (Brown 1999). Because 
of the probable confounding effect of numerous expo-
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sures to other chemical agents in these populations, 
the studies do not provide adequate evidence of a 
relationship between nitrosamine exposure and cancer 
in the humans. Several authors have suggested that 
nitrosamines are responsible for an excess of cancers 
of the bladder, lung, stomach and other sites noted in 
studies of workers in the rubber industry. The Interna-
tional Agency for Research on Cancer (IARC) has identi-
fied the exposure in rubber industry as a carcinogenic 
risk to humans. 
Risk assessment
A number of quantitative risk assessments have been 
developed for nitrosamines under different conditions 
of exposure. The Environmental Protection Agency 
has calculated a level of 7 ppt NDMA in water as repre-
senting a 10-6 risk for cancer. On the basis of intake, the 
state of California has determined that 0.04 and 0.004 
µg/m3 of NDMA per day were equivalent to a 10-5 and 
10-6 risk of cancer, respectively.
Regulation and occupational exposure limits
IARC has classified NDMA and NDEA as group 2A 
carcinogens (probable human carcinogens), and 
nitrosodibutylamine, nitrosodipropylamine, nitro-
somorpholine, nitrosopiperdine and nitrosopyrroli-
dine, as group 2B carcinogens (possible human carcin-
ogens). At present there are no established numerical 
exposure limits in the workplace in the US. In Germany, 
numerical regulations for occupational exposure to 
nitrosamines have been established. The guidelines 
are intended to apply to nitroamines as a class, and in 
general industry, the total exposure to nitrosamines 
cannot exceed a technical orientation value of 1 µg/m3 
(measured as an 8 hour time-weighted average).
Health risk evaluation
The amines relevant for the CO2 capture may be 
degraded to different nitrosamines. The possible 
concentration of the different nitrosamines in the air 
is uncertain. Therefore, this health risk evaluation is 
general. Based on experimental data, there seems little 
doubt that some nitrosamines are extremely potent 
carcinogens, that can pose a serious hazard to humans 
if present in the environment. In animal carcino-
genicity experiments, the absence of a lower no-effect 
threshold for N-nitroso compounds makes it desirable 
to reduce the human exposure to these compounds to 
an absolute minimum. 
Nitramines
N-nitramines can be produced as atmospheric pollutants 
when secondary amines react with NO2. N-nitramines are 
structurally related to N-nitrosamines, with the nitroso 
group being replaced by a nitro group. Compared to the 
nitrosamines, there are few studies on the health effects 
of nitramines. The following is a general discussion of 
available data on aliphatic nitramines. 
Metabolism
The metabolic pattern of aliphatic N-nitramines seems 
to resemble that of corresponding N-nitrosamines, 
except that N-nitromonoalkylamine metabolites were 
identified. N-nitrodimethylamine can be oxidized 
by the cytochrom P450 enzyme family (possibly 
CYP2E1) to N-nitro-hydroxymethyl methylamine, a 
stable compound that can be further metabolised to 
the demethylated compound N-nitromethylamine 
and to formaldehyde. N-nitromethylamine has been 
found to be relative stable. N-nitrodimethylamine 
can also be reduced to the carcinogenic nitrosamine, 
N -nitrosodimethylamine. In a study by Hassel et 
al. (1990), the metabolism of radioactively labelled 
N-nitrodimethylamine in rats was compared with that 
of N-nitromethylamine. The study indicates that in 
contrast to N-nitrodimethylamine, N-nitromethylamine 
is only oxidized to a minor extent. 
Toxicity
Acute toxicity
N-nitrodimethylamine has a LD50 of about 1000 mg/kg 
bw (Druckrey et al., 1967; Andersen et al, 1978) upon oral 
exposure of rats. The rats appeared normal 4-24 hr after 
dosing, but became increasingly lethargic thereafter. 
Focal areas of hemorrhage were found in the stomach 
and intestine and variable amounts of clear fluid in the 
peritoneum. The liver appeared normal in all rats. 
Mutagenicity
The mutagenic and carcinogenic activity of aliphatic 
N-nitramines seem in general to be much lower than 
those of the corresponding nitrosamines. However, 
data on mutagenicity are test system dependent. It is 
recognised that certain classes of mutagens including 
short chain aliphatic nitrosamines are not always 
detected using standard procedures. The technical 
guidelines (CPS&Q) suggest the use of E. coli WP2 
strains or S. typhimurium TA102 for testing of these 
substances which have an AT base pair at the primary 
reversion site. Thus the negative results of some of the 
earlier bacterial mutagenicity data may be explained 
by the properties of the bacterial strain used in the 
tests.
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Several of the N -nitramines or their metabolites 
have been found to be mutagenic in the E. coli WP2 
hcr- assay, but were non-mutagenic in the Salmonella 
TA 100 and TA 1535 strains. The mono-methylated 
N-nitramines are clearly mutagenic in several assays, 
whereas the dimethylated analogues show borderline 
mutagenicity (Khudoley ;Suzuki, 1985; Frei et al, 1986). 
Formaldehyde has been proposed to be the muta-
genic metabolite of N-nitrodimethylamine responsible 
for its mutagenicity in the Salmonella TA100 system. In 
contrast, both formaldehyde and N-nitro-hydroxyme-
thyl methylamine were negative in mammalian cell 
mutagenicity assays (Frei, 1986). N-nitrodimethyl-
amine, however, damaged hepatic DNA in mice in vivo. 
Although being a directly acting mutagen in the E. coli 
WP2 hcr- assay, results indicate that further metabolism 
of N-nitromethylamine, possible to the highly reac-
tive N-nitrosomethyl compound and ultimately to the 
methyldiazonium ion, might occur in mammalian cells.
Carcinogenicity
Pliss et al. (1982) reported on the carcinogenicity  of 
N-nitrodimethylamine, N-nitrodiethylamine and 
N-nitrobutylamine in various species including rats. 
Rats were given 200 ppm (15-20 mg/kg bw) daily of 
test substance in the drinking water for 130 weeks. In 
this study only N-nitrodiethylamine was found to be 
carcinogenic (liver tumours).
Several other studies show that N-nitrodimethylamine 
is carcinogenic to rats (Druckrey, 1967; Goodall and 
Kennedy, 1976; Mirvish, 1980, Scherf 1989). When 
N-nitrodimethylamine was administered via drinking 
water, tumours in the liver and kidney seemed to 
dominate. The morphology of the liver tumours 
after N-nitrodimethylamine treatment was said to 
contrast with that often described after treatment 
with N-nitrosodimethylamine. In a comparative carci-
nogenicity study (Scherf et al, 1989), rats were admin-
istered N-nitrodimethylamine or N-nitromethylamine 
once weekly by oral gavage. N-nitrodimethylamine 
induced mainly neurogenic tumours of the nasal 
cavity, whereas N-nitromethylamine induced neuri-
noma of the spine and spinal and peripheral nerves. 
N-nitromethylamine was slightly less potent than the 
dimethyl compound. It was suggested that a bolus 
effect could explain the differences in target organ 
seen between this study and the drinking water 
studies. Later studies by the same authors indicate that 
high doses of N-nitrodimethylamine inhibit the hepatic 
effects of the nitrosamine metabolite.
Health risk evaluation
We have made a literature study of the toxicological 
information on the potential nitroalkylamines listed 
in ”Organic compounds included in the CAS Register” 
in the report from the University of Oslo of May 13, 
2008.  Data on health effects of aliphatic N-nitramines 
are sparse. However, there is sufficient information 
to conclude that several of the nitramines are muta-
genic and carcinogenic in rodents, although they 
seem considerably less potent than corresponding 
nitrosamines. It would seem that several of the cellular 
mutagenicity assays are not well suited to study the 
mutagenic potential of nitramines, due to insufficiencies 
of the traditional metabolic activation systems used. 
Nitramine (synonyme)
Methanamine, N-nitro- 
(N-Nitromethylamine)
C H4 N2 O2 598-57-2
Methanamine, N-Methyl-N-nitro-
Dimethylnitramine 
N-Nitrodimethylamine
C2 H6 N2 O2 4164-28-7
Methanol, (methylnitroamino)- 
(Methylnitramino)methanol
C2 H6 N2 O3 32818-80-7
Ethanamine, N-ethyl-N-Nitro- 
N-Nitrodiethylamine 
Diethylnitramine
C4 H10 N2 O2 7119-92-8
N-Nitrodibutylamine 4164-31-2
Table: Nitroalkylamines included in the CAS Register.
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Aldehydes
An aldehyde is an organic compound containing a 
terminal carbonyl group. This functional group, which 
consists of a carbon atom bonded to a hydrogen atom 
and double-bonded to an oxygen atom (chemical 
formula O=CH-), is called the aldehyde group. 
Aldehydes are major products in the photooxidation 
of hydrocarbons, and in the reactions of hydrocarbons 
with ozone, oxygen atoms, or free radicals. Formal-
dehyde and acrolein have been specifically identi-
fied in urban atmospheres. These materials probably 
contribute to the odour and eye irritation produced by 
photochemical smog (Amdur et al., 1991). 
Formaldehyde
Formaldehyde (CAS No.:50-00-0), also called methanal, 
is a flammable, colourless and readily polymerized 
gas at ambient temperatures. Formaldehyde is readily 
soluble in water, alcohols, and other polar solvents, 
but has a low degree of solubility in non-polar fluids. 
Formaldehyde decomposes at 150 ˚C into methanol 
and carbon monoxide; in general it is highly reac-
tive with other chemicals. In sunlight, it is readily 
photo-oxidized to carbon dioxide (EHC 89, 1989). 
Direct release to the aquatic compartment and soil is 
expected to be minor and significant removal occurs 
through biodegradation (NICNAS, 2006). 
The substance is currently classified as follows: 
C >= 25% 
T ;  R23/24/25 (Toxic by inhalation, in contact with skin  
       and if swallowed)
       R34 (Causes burns)
       R40 Cat 3 (Limited evidence of a carcinogenic                       
       effect)
       R43 (May cause sensitization by skin contact)
Exposure
A considerable amount of formaldehyde comes from 
the exhaust emissions of motor vehicles. Formalde-
hyde is an important raw material in industry. It is used 
in the manufacture of synthetic resins and chemical 
compounds such as lubricants, adhesives and fertilizers. 
It has also applications as disinfectant, preservative 
and in cosmetics (EHC 89, 1989).  There is some natural 
formaldehyde in raw food with levels ranging from 1 mg/
kg up to 90 mg/kg. An accidental contamination of food 
may occur through fumigation, the use of formaldehyde 
as a preservative, or through cooking. Tobacco smoke as 
well as urea-formaldehyde foam insulation and formalde-
hyde-containing disinfectants are all important sources of 
formaldehyde in the indoor environment. 
Formaldehyde concentrations in indoor air are gene-
rally higher than outdoors. Levels of formaldehyde in 
outdoor air are generally below 1 µg/m3 in remote 
areas and below 20 µg/m3 in urban settings. The 
levels of formaldehyde in the indoor air of houses are 
typically 20-60 µg/m3 (IARC, 2006). It is estimated that 
several million people are exposed occupationally to 
formaldehyde in industrialised countries alone. The 
highest continuous exposures (frequently > 1 mg/m3) 
have been measured in particle-board mills, during the 
varnishing of furniture and wooden floors, in foundries, 
during the finishing of textiles and in fur processing  
(IARC, 1995).
Toxicity
Toxicokinetic. In humans and experimental animals, 
formaldehyde is readily absorbed by all exposure 
routes (EHC 89). More than 90% of inhaled formalde-
hyde gas is absorbed in the upper respiratory tract of 
rats and monkeys (IARC 1995). When inhaled, it reacts 
rapidly at the site of contact and is quickly metabolised 
in the respiratory tissue (EHC 89, 1989). 
Irritation. The common effects of formaldehyde expo-
sure to humans are various symptoms caused by 
irritation of the mucosa in the eyes and upper airways. 
Concentrations of 0.6-1.2 mg/m3 (0.5 -1 ppm) are 
detectable by odour to most people. The suggested 
threshold level for exposure to formaldehyde,  associ-
ated with reported mild to moderate upper respiratory 
tract irritation of humans in controlled studies, is also 
approximately 0.6-1.2 mg/m3 (0.5-1.0 ppm), whilst the 
threshold for conjunctival eye irritation in most healthy 
people appears to be > 1.2 mg/m3 (1 ppm). Tolerance 
to the irritation effects (accommodation) has been 
reported to occur in individuals subjects to prolonged 
exposure (COMEAP, 2000; Arts et al., 2006). 
Sensitisation. In the non-industrial indoor environment, 
sensory reactions are typical effects, but there are large 
individual differences in the normal population, and 
between hyperreactive and sensitized people. There 
are a few case reports of asthma-like symptoms caused 
by formaldehyde, but none of these demonstrated a 
sensitization effect and the symptoms were considered 
to be due to irritation. Skin sensitization is induced 
only by direct skin contact with formaldehyde solu-
tions in concentrations higher than 2%. The lowest 
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patch test challenge concentration in an aqueous 
solution reported to produce a reaction in sensitized 
persons was 0.05% formaldehyde (NICNAS, 2006). 
Carcinogenicity. Formaldehyde is genotoxic, but only 
in the presence of cytotoxicity it may lead to cancer 
(COMEAP, 2000). For cytotoxicity of formaldehyde, 
concentration is more important than the duration of 
the exposure (IARC, 1995). Carcinogenicity bioassays 
in rats have shown that exposure to concentrations 
> 6.9 mg/m3 (5.6 ppm) formaldehyde vapour induce 
development of tumours in the nasal cavity. The dose 
response curve is highly non-linear, with a dispro-
portionate increase in tumour incidence at higher 
levels, suggesting that cytotoxicity may be the rate-
limiting step in this process. Formaldehyde is classified 
as a potential human carcinogen, based on limited 
evidence in humans and sufficient evidence in experi-
mental animals. Human epidemiological data relate to 
a potential association of nasopharyngeal cancer with 
occupational exposures to formaldehyde. Limited data 
also suggest an association between formaldehyde 
and nasal cancers and leukaemia. Generally exposure 
levels in human studies have not been well evaluated 
(COMEAP, 2000).
Other effects. There is no significant evidence that 
formaldehyde is toxic to the immunesystem, the repro-
ductive system, or to developing foetuses (COMEAP, 
2000).
Health risk evaluation
In rodents and monkeys, a no-observable-effect level 
(NOEL) of 2.5 mg/m3 for inhaled formaldehyde has 
been suggested (IARC, 1995). Sensory irritation and 
odour is first observed at a level of approximately 1.2 
mg/m3. However, lower levels for irritation and odour 
may occur. From both human and animal studies, it has 
been concluded that at airborne levels for which the 
prevalence of sensory irritation is minimal both in inci-
dence and degree (i.e., <1.2 mg/m3), risks of respiratory 
tract cancer are considered to be negligibly low (Arts, 
2006, NICNAS, 2006). In Norway, The Board of Health 
Supervision has set a threshold for formaldehyde in 
the indoor environment at 100 μg/m3 (0.1 ppm).
Acetaldehyde 
Acetaldehyde (CAS No.:75-07-0) is a colorless volatile 
liquid with a pungent suffocating odour. Acetalde-
hyde is a highly flammable and reactive chemical that 
is miscible with water and most common solvents. 
Because of its high reactivity, intercompartmental 
transport of acetaldehyde is expected to be limited. 
Some transfer of acetaldehyde to air from water and 
soil is expected because of the high vapour pressure 
and low sorption coefficient. It is suggested that the 
photo-induced atmospheric removal of acetaldehyde 
occurs predominantly via radical formation. Photolysis 
is also expected to contribute to the removal process. 
Both processes cause a reported daily loss of about 
80% of atmospheric acetaldehyde emissions. Reported 
half-lives of acetaldehyde in water and air are 1.9 h and 
10-60 h, respectively (EHC 167, 1995). 
The substance is currently classified as follows:
        R12 (Extremely flammable)
        R36/37 (Irritating to eyes and respiratory system)
 Xn; R40 Cat 3 (Limited evidence of a carcinogenic 
effect)
Exposure
The main source of exposure to acetaldehyde in the 
general population is through metabolism of ethanol 
where acetaldehyde is a metabolic intermediate. Addi-
tionally the general population is exposed to acetal-
dehyde from food products and beverages, but to a 
lesser extent from air. The contribution from drinking 
water is negligible. Acetaldehyde is also present in 
vehicle exhaust and in wastes from various indus-
tries. Degradation of hydrocarbons, sewage and solid 
biological wastes produces acetaldehyde, as well as 
the open burning and incineration of gas, fuel oil and 
coal. Workers may be exposed in some manufacturing 
industries and during alcohol fermentation, where the 
principal route of exposure is most likely inhalation 
and possible dermal contact (EHC 167, 1995). WHO 
(1995) summarised the mean concentrations of acetal-
dehyde in ambient air, based on data from various 
locations around the world, as within the range of 
2-8.6 µg/m3 (0.0011-0.0048 ppm).
Toxicity
Toxicokinetic. Available studies on toxicity indicate 
that acetaldehyde is absorbed through the lungs and 
gastrointestinal tract. Absorption through the skin is 
also probable. Following inhalation by rats, acetalde-
hyde is distributed to the blood, liver, kidney, spleen, 
heart, and other muscle tissues. Low levels were 
detected in embryos from rodents after maternal intra-
peritoneal injection of acetaldehyde and following 
maternal exposure to ethanol. Potential production 
of acetaldehyde has also been observed in rat fetuses 
and in the human placenta, in vitro. Following oral 
administration, virtually no unchanged acetaldehyde 
is excreted in the urine. Endogenous production and 
metabolism of acetaldehyde occurs mainly in the 
liver, primarily as a result of ethanol metabolism. The 
majority of ethanol is metabolised by mitochondrial 
enzymes (aldehyde dehydrogenases), of which a 
number of polymorphic forms have been identified 
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(COMEAP, 2000). Acetaldehyde has been implicated as 
the putatively toxic metabolite in the induction of 
ethanol associated liver damage, facial flushing and 
developmental effects (EHC 167, 1995). 
Irritation. Acute exposure to acetaldehyde vapour 
has been associated with irritation of the eyes, skin 
and respiratory tract. Limited studies with human 
volunteers showed short-term exposure thresholds 
of 90 mg/m3 (50 ppm) for eye irritation and 241 mg/
m3 (134 ppm) for upper respiratory tract irritation, in 
most subjects. Some subjects experienced eye irrita-
tion at 45 mg/m3 (25 ppm) exposure. The reported 
effect levels were all far above the reported odour 
threshold at 0.09 mg/m3. All subjects showed tran-
sient conjunctivitis associated with exposure to 360 
mg/m3 (200 ppm) acetaldehyde vapour for 15 min 
(COMEAP, 2000). Respiratory effects were also noted in 
hamsters exposed to acetaldehyde by inhalation and 
degenerative changes were observed in the trachea. 
Degenerative changes in respiratory epithelium and 
larynx were noted at higher concentrations (EHC 167, 
1995). No-observed-adverse-effect-levels (NOAELs) 
of 270 mg/m3 (150 ppm) and 700 mg/m3 (390 ppm) 
have been identified for respiratory tract lesions in rats 
and hamsters, respectively (COMEAP, 2000). A small 
number of studies have shown that inhaled acetal-
dehyde causes broncho-constriction and increases 
non-specific bronchial responsiveness in asthmatic 
patients, but not in healthy controls (COMEAP, 2000). In 
repeated dose studies, both using oral and inhalation 
routes, the toxic effects at relatively low concentrations 
were limited to the sites of initial contact (EHC 167).  
Genotoxicity and carcinogenicity. Acetaldehyde is classi-
fied by IARC, US EPA and ECB as possibly carcinogenic 
to humans.
A LOAEL of 1350 mg/m3 (750 ppm) was set for hyper-
plastic changes and tumour incidence (adenocarci-
nomas of the olfactory epithelium) in rats (COMEAP, 
2000). Acetaldehyde is genotoxic in vitro, inducing 
gene mutations, clastogenic effects and sister chro-
matid exchanges (SCEs) in mammalian cells in the 
absence of exogenous metabolic activation. Negative 
results were found in tests for bacterial mutacenicity 
(Ames` test). Following intraperitoneal injection, 
acetaldehyde induced SCEs in the bone marrow of 
Chinese Hamsters and mice. 
Increased incidences of tumours have been noted in 
inhalation studies on rats and hamsters. In rats, there 
were dose related increases in nasal adenocarcinomas 
and squamous cell carcinomas (significant at all dose 
levels). In hamsters, increases in nasal and laryngeal 
carcinomas were non-significant (EHC 167, 1995). It has 
been suggested that the mechanism of carcinogenicity 
observed with acetaldehyde is very similar to the 
mechanism of carcinogenicity of formaldehyde, but 
higher doses of acetaldehyde were required to observe 
the same effects as with formaldehyde (COMEAP, 
2000).
Developmental toxicity. Exposure of pregnant rats and 
mice to acetaldehyde induced fetal malformations 
(EHC 167, 1995). Several animal studies have demon-
strated direct teratogenic effects of acetaldehyde 
when applied to embryos in vitro and in vivo, and it has 
been suggested that the compound may contribute 
to the congenital abnormalities seen in human 
foetal alcohol syndrome. There are, however, no data 
regarding the developmental and reproductive toxicity 
of inhaled acetaldehyde in humans or experimental 
animals (COMEAP, 2000).
Health risk evaluation
On the basis of data on irritancy in humans, a toler-
able concentration of 2 mg/m3 has been derived for 
acetaldehyde. The mechanism of carcinogenicity 
observed with acetaldehyde has been suggested to 
be very similar to the mechanism of carcinogenicity 
of formaldehyde (COMEAP 2000). Hence, exposure to 
acetaldehyde concentrations < 2 mg/m3 is not likely to 
cause respiratory tract cancer. However, in 1995 WHO 
suggested a tolerable concentration of 0.3 mg/m3 for 
lifetime cancer risk (EHC 167, 1995).
Amides
There seems to be a common effect pattern of forma-
mides as one group and of acetamides as the other. 
The majority of the animal studies are performed on 
N,N-dimethylformamide (DMF), N-methylformamide 
(MMF), N,N-dimethylacetamide (DMAC) and  N-methy-
lacetamide (MMAC). In this part we will discuss health 
effects only of formamide and acetamide. 
Formamide 
Formamide (CAS no: 75-12-7) , CONH2, known as meth-
anamide, is derived from formic acid. Formamide is a 
clear liquid which is miscible with water and has an 
ammonia-like odour.  It is used primarily for manufac-
turing sulfa drugs, synthesizing vitamins, as a softener 
for paper and fiber as well as in the dye industry. 
Formamide, in its pure state, has been used as an alter-
native solvent for the electrostatic self-assembly of 
polymer nanofilms (Vimal et al.,2007). Formamide will 
begin to partially decompose into carbon monoxide 
and ammonia at 180°C. When heated strongly, forma-
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mide decomposes to hydrogen cyanide (HCN) and 
vapor (H2O). 
Classification: Repr. Cat 2 R61.
Metabolism
Formamide is a metabolite of DMF. DMF is oxidised by 
cytochrome P450 (probably Cyp2E1) to N-hydroxyme-
thyl-N-methylformamide (HMMF) which is demethyl-
ated to MMF, which is further demethylated to forma-
mide. In humans the most important target organ is 
the liver and the metabolites is excreted in the urine. 
More than 90% of DMF is retained in the respiratory 
tract of exposed human volunteers (Mraz, 1992).  The 
metabolic pathway of DMF seems to be qualitatively 
different in rodents and humans,  since in rodents the 
major excreted metabolite in urine is HMMF followed 
by formamide, while in humans it is DMF>HMMF>N-
acetyl-S-(N-methylcarbamoyl)cystein (Tulip, 1989; 
Kestell, 1986). 
Experimental toxicity
The toxicity data is based on ECBI/59/98-Add.4 (2000).
Acute toxicity. The LD50 values in rats was between 
3,200 mg/kg bw and 7,500 mg/kg bw, a LC50 value after 
inhalation was > 21 mg/l/4 hours (furthermore no toxic 
effects at 7.2mg/l/6h) and acute dermal toxicity values 
in rats and rabbits > LD50 17,000 mg/kg (ECBI 2000). 
Repeated sublethal treatment by various exposure 
routes shows the liver to be the target organ with the 
degree of damage being proportional to the amount 
absorbed. However, massive doses can also produce 
damage to other organs and tissues (Kennedy 1986).
Skin irritation. Three older tests in rabbits show either 
no irritancy (two tests) or only erythema after 20-hour 
exposure.
Eye irritation. Whereas some older studies showed 
some slight to moderate irritant effects, in a more 
recent study no irritating effects according to EC 
criteria were observed. Two of the older studies 
excluded iris damage or showed only mild iritis in part 
of the animals.
Subacute, subchronic and chronic toxicity. In a 4-week 
study 113 mg/kg bw did not show toxic effects besides 
some retarded body weight gain at the end of the 
treatment, whereas 340 mg/kg bw caused severe 
toxicity (mortality). It can be assumed that at the limit 
of 150 mg/kg bw (28-day study) no “severe lesions” will 
be caused.
There are no appropriate, subchronic (90 days) studies 
to  assess effects by inhala tion. From a 2-week study 
a definitive conclusion cannot be made, but it may 
be assumed that serious damage is not likely to be 
achieved at the limit dose of 0.25 mg/l/6 h/d also taking 
into account the results of the 90-day dermal studies.
In a recent dermal 90-day study the NOAEL with 
respect to effects was 300 mg/kg bw/day for females, 
whereas only slight hematological effects were found 
at this dose for males.
Mutagenicity. The National Toxicology Program tested 
formamide for mutagenicity in the Salmonella/micro-
some preincubation assay using the standard protocol. 
Formamide was tested at several doses in five Salmo-
nella typhimurium strains in the presence and absence 
of rat or hamster liver enzymes. Formamide was nega-
tive in these tests and the highest ineffective dose 
tested in any S. typhimurium strain was 10 mg/plate 
(Mortelmans et al; 1986).
Carcinogenicity. Formamide appear to be non-carcino-
genic (Kennedy, 1986).
Reproductive toxicity. Embryotoxicity can be demon-
strated at high doses, which generally show toxicity 
to the maternal animals. Structural abnormalities 
in sensitive species such as the rabbit are produced 
following exposure at near-lethal levels. The spectrum 
of abnormalities seen is broad and fails to show any 
time or site specificity in terms of developing organs/
organ systems.
The developmental toxicity potential of orally admin-
istered formamide was evaluated in rats (25 animals/
group). Formamide (50, 100, or 200 mg/kg bw/day) was 
administered by gavage on gestation day 6-19. At 200 
mg/kg/day, maternal body weight, weight gain and 
pregnant uterine weight were significantly decreased. 
Maternal gestational weight gain (corrected for gravid 
uterine weight), liver weight, food and water consump-
tion were not affected. Formamide did not affect prenatal 
viability or incidences of fetal malformations or variations. 
Average fetal body weight/litter was decreased at 100 
and 200 mg/kg bw/day. Fetal body weight was affected 
at lower daily doses than in previous studies, possibly due 
to the longer total exposure period and lack of a recovery 
period between cessation of exposure and termination. 
In summary, the maternal toxicity NOAEL was 100 mg/kg 
bw/day. The developmental toxicity NOAEL was 50 mg/
kg bw/day (Price et al., 1999).
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Human toxicity
Liver damage can be produced by overexposure to 
these chemicals in man. Airborne concentrations need 
to be controlled and care should be taken to avoid 
excessive liquid contact as the chemicals are absorbed 
through the skin and the respiratory tract (Kennedy 
1986 and 2001).
Acetamide
Acetamide (CAS no: 60-35-5) or acetic acid amide or 
ethanamide (CH3CONH2) the amide of acetic acid, is a 
white crystalline solid in pure form and produced by 
dehydrating ammonium acetate. Acetamide is used 
primarily as a solvent and a plasticizer and a wetting 
and penetrating agent (U.S. Department of Health and 
Human Services. Hazardous Substances Data Bank, 
1993).  The derivative N,N-dimethylacetamide (DMA), 
which has two methyl groups replacing the amine 
protons, is used as a solvent. 
Classification: Xn; Carc. Cat 3; R40
Acetamide is a metabolite of N,N-dimethylacetamide 
(DMAC). DMAC is metabolised through an analogous 
pathway as DMF to N-methylacetamide (MMAC), 
which is demethylated to acetamide.
Experimental toxicity
The toxicity data is based on US EPA(2000) and Lakes 
environmental software air toxics index.
Acute effects. Acetamide causes mild skin irritation 
in humans from acute exposure (U.S. Department of 
Health and Human Services. Hazardous Substances 
Data Bank, 1993). Tests involving acute exposure of rats 
and mice have shown acetamide to have low to mode-
rate acute toxicity from oral exposure (U.S. Department 
of Health and Human Services Registry of Toxic Effects 
of Chemical Substances, 1993). Tests involving acute 
exposure of animals, such as the LD50 test in rats and 
mice, 7 g/kg bw and 12.9 g/kg bw, respectively, have 
shown acetamide to have low to moderate acute 
toxicity from oral exposure (U.S. Department of Health 
and Human Services, 1993; Nippon,Y.Z., 1968).
Subacute, subchronic and chronic toxicity. No informa-
tion is available on subacute, subchronic or chronic 
effects of acetamide in humans or animals.
Reproductive/developmental effects. No information is 
available on the reproductive or developmental effects of 
acetamide in humans. Animal studies have not reported 
any significant developmental effects from exposure to 
acetamide (U.S. Department of Health and Human Serv-
ices. Hazardous Substances Data Bank, 1993).
Mutagenicity. Acetamide is considered a non-genotoxic 
carcinogen that was negative in at least six separate 
genotoxicity assays (Parodi et al., 1991). There were no 
evidence for genotoxicity in Salmonella typhimurium, 
for DNA damage in rat hepatoma cells or for DNA 
repair in isolated rat hepatocyte (Dybing et al.,1987). 
Mice exposed orally to acetamide (50 mg/kg bw 30 
and 6 h prior to sacrifice), produced increases in the 
bone marrow micronuclei (Chieli et al., 1987; Arni, 
1989). In contrast to these findings, in a study by 
Mirkova (1996), acetamide is inactive as a micronucleus 
inducing agent in mouse bone marrow. Positive effects 
were seen in micronuclei from Syrian hamster embryos 
exposed in vitro (Fritzenschaf et al., 1993).
Carcinogenicity. The carcinogenicity bioassay by Fleis-
chman et al. (1980) indicated that acetamide causes 
hematopoietic tumors in male C57BL/6 mice, and 
hepatocellular carcinomas in male and female Fischer 
344 rats. Rats were more sensitive than mice, and male 
rats were more sensitive than female rats in this study. 
Several animal studies have reported liver tumors from 
oral exposure to acetamide (U.S. Department of Health 
and Human Services. Hazardous Substances Data 
Bank, 1993; IARC, 1987, 1974; California environmental 
protection agency, 1999). 
Human toxicity
No studies on the potential carcinogenic effects of 
acetamide on humans are known to exist. Occupa-
tional exposure to acetamide may occur for workers in 
the plastics and chemical industries (U.S. Department 
of Health and Human Services. Hazardous Substances 
Data Bank, 1993). The acute exposure (short-term) 
causes mild skin irritation. No information is avail-
able on the chronic (long-term), reproductive/devel-
opmental, or carcinogenic effects of acetamide in 
humans. Reference Concentration (RfC) for acetamide 
is under review by EPA. EPA has not classified acet-
amide for carcinogenicity. The International Agency for 
Research on Cancer (IARC) has classified acetamide as 
a Group 2B, possible human carcinogen (IARC, 1987) 
and ECB (CPS&Q) has classified acetamide as a carc. 
cat.3 R40 (Limited evidence of a carcinogenic effect). 
The California Environmental Protection Agency 
(1999) has established an inhalation unit risk estimate 
of 2.0x10-5(µg/m3)-1 and an oral cancer slope factor of 
7.0x10-2 (mg/kg/d)-1 for acetamide.
Health risk evaluation of amides
We have made a literature study of the human toxi-
cological information on the potential formamides 
and acetamides. The studies on formamide indicates 
concern for developmental toxicity. The carcino-
genicity studies on acetamide indicate liver tumour 
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formation in rats. Occupational exposure to aceta-
mides induces mild skin irritation.
Concluding remarks for the  
degradation products
The amines relevant for the CO2 capture may be degra-
dated to different nitrosamines, nitramines, aldehydes 
and amides. Data on health effects of the specific 
degradation products are sparse. This report of health 
risk evaluation is, therefore, general. Based on experi-
mental data, there seems little doubt that some nitro-
samines are extremely potent carcinogens, that can 
pose a serious hazard to humans if present in the envi-
ronment. It is desirable to reduce the human exposure 
to these compounds to an absolute minimum. Several 
of the nitramines are mutagenic and carcinogenic in 
rodents, although they seem considerably less potent 
than the corresponding nitrosamines.
With regard to the aldehydes, it has been concluded 
that at airborne levels for which the prevalence of 
sensory irritation is minimal, both in incidence and 
degree (<1.2 mg/m3), risks of respiratory tract cancer 
are considered to be negligibly low. The degradation 
products formamide and acetamide has been reported 
to induce development toxicity and carcinogenicity, 
respectively, in experimental animals. Acetamide 
may also induce skin irritation. The irritating potential 
of the aldehydes and amides might in this context 
be the most relevant adverse health effect of these 
compounds, as also the amines thought to be used 
in the CO2 capture also has such effects. Therefore, all 
these compounds have to be evaluated together with 
respect to irritating potential of the air around the gas 
plants. 
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